GLP-1 Receptor Agonists Linked to Higher Hypotension Risk in Hypertension Patients, Study Finds

Patients taking GLP-1 receptor agonists for weight loss or diabetes management face a higher risk of hypotension compared to those not using the medications, according to a study presented at the Endocrine Society’s annual meeting in June 2026. The research, led by Dr. Micah J. Eimer of Northwestern Medicine, analyzed data from 54,682 individuals on antihypertensive therapies and found elevated hypotensive events among GLP-1 users.

Key Findings of the Study

Among patients on GLP-1 receptor agonists—such as liraglutide, semaglutide, and tirzepatide—rates of hypotensive episodes were significantly higher at 6, 12, and 24 months compared to nonusers. At 6 months, 10.2% of GLP-1 users experienced hypotension versus 8.7% of nonusers (P < .001). The disparity widened over time, with 14.3% of GLP-1 users reporting hypotension at 12 months versus 13.6% of nonusers (P = .003).

Hypotension was most prevalent in patients aged 65 or older and those with type 2 diabetes, according to the study. Dr. Eimer noted that these findings align with clinical observations of lightheadedness and fainting in patients starting GLP-1 therapies. “Hypotension is a critical side effect that demands close monitoring,” he said, emphasizing the need for caution in prescribing these medications.

Implications for Patient Care

The study highlights the importance of blood pressure monitoring for patients initiating GLP-1 therapy. Nearly 25% of participants had their antihypertensive medications adjusted during the study period, often due to hypotension. Researchers found that weight loss alone did not fully explain the increased hypotension risk, suggesting additional mechanisms such as direct blood pressure-lowering effects or interactions with other medications.

Dr. Eimer warned that patients obtaining GLP-1 drugs without clinical oversight face heightened risks. “These medications are effective for weight loss, but their use requires careful management,” he said. “Healthcare providers should educate patients on symptoms of low blood pressure and adjust therapies as needed.”

Call for Further Research

While the study underscores the risks, researchers stressed the need for larger trials to identify high-risk populations and explore factors like medication combinations and weight loss rates. “Understanding these dynamics will help tailor treatments to minimize harm while maximizing benefits,” Eimer said.

The findings add to ongoing debates about the safety of GLP-1 receptor agonists, which have become widely prescribed for obesity and diabetes. Regulatory agencies and medical societies are expected to review the data as they update guidelines for these therapies.